Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
As CEO, my north star in this crisis is unequivocally patient safety. The "wait for more data" approach is a catastrophic trap—both ethically and legally. History (e.g., Vioxx, Fen-Phen) shows that delaying disclosure of a known severe adverse event transforms a medical safety issue into corporate fraud, manslaughter…Read the full answer
48-Hour Action Plan: Patient Safety First Critical Reality Check First Your legal team's "6 months" likely refers to a full label revision, not initial safety signal reporting. FDA requires serious unexpected adverse events reported within 15 days (7 days if fatal).Read the full answer